Celyad Oncology SA · DUS:1C0

Celyad Oncology SA financial statements

Celyad Oncology SA's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue21.0K186.0K102.0K005.00K6.00K3.12M3.54M10.0M
Cost of revenue-1.91M12.0K69.0K00000515.0K1.54M
Gross profit1.93M173.0K33.0K005.00K6.00K3.12M3.02M8.47M
Research and development3.28M3.23M4.60M18.9M20.8M21.5M25.2M23.6M22.9M27.7M
Selling, general and administrative1.70M3.20M6.03M10.5M9.91M9.31M8.72M9.01M9.31M9.74M
Operating income-7.18M-5.86M-8.46M-40.9M-26.4M-17.0M-28.9M-38.2M-52.9M-25.6M
Depreciation and amortization172.0K347.0K285.0K827.0K1.30M1.64M1.79M1.11M9.00M1.52M
EBITDA-7.01M-5.51M-8.17M-40.0M-25.1M-15.4M-27.1M-37.1M-43.9M-24.1M
Interest expense64.0K119.0K84.0K198.0K255.0K434.0K343.0K62.0K144.0K109.0K
Income before tax-656.0K-5.82M-8.51M-40.9M-26.5M-17.2M-28.6M-37.4M-56.4M-23.6M
Income tax-1.49M0-63.0K65.0K10.0K0-8.00K-1.11M-1.00K-6.00K
Net income830.0K-5.82M-8.45M-40.9M-26.5M-17.2M-28.6M-37.4M-56.4M-23.6M
Earnings per share, basic0.02-0.14-0.34-1.81-1.70-1.23-2.29-3.36-5.86-2.53
Earnings per share, diluted-0.14-0.34-1.81

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.71M4.20M7.00M12.4M30.0M17.2M39.3M40.5M23.3M48.4M
Short-term investments00009.20M10.7M34.2M
Receivables792.0K170.0K457.0K1.12M668.0K615.0K2.70M1.27M81.0K1.11M
Inventory0417.0K1.26M1-2.14M1.56M111642.0K
Current assets3.50M6.51M11.1M14.8M34.3M19.7M42.8M51.7M36.4M85.4M
Property, plant and equipment1.49M1.83M309.0K3.25M4.12M5.06M3.01M3.29M3.56M
Goodwill00342.0K0883.0K883.0K883.0K883.0K914.0K1.04M
Total assets4.30M9.93M16.3M19.7M79.9M66.1M89.8M94.3M77.6M138.8M
Accounts payable511.0K1.23M1.24M4.75M6.61M4.74M6.97M5.92M4.80M8.10M
Current liabilities1.82M2.85M2.93M10.4M13.8M11.8M11.9M9.65M7.95M11.3M
Long-term debt00037.0K229.0K326.0K536.0K
Total debt17.5M1.06M0037.0K4.36M1.65M1.44M1.48M
Total liabilities1.86M26.0M9.98M15.4M36.3M35.1M44.2M38.7M30.1M47.9M
Shareholders' equity2.44M511.0K6.30M4.32M31.0M31.0M45.6M55.6M47.5M90.9M
Shares outstanding46.3M41.4M25.7M22.6M15.6M13.9M12.5M11.1M9.62M9.33M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-6.90M-5.68M-15.2M-28.0M-26.6M-27.7M-28.2M-27.2M-49.5M-24.7M
Capital spending00-899.0K-123.0K-331.0K-150.0K-622.0K-1.76M-858.0K-1.78M
Free cash flow-6.90M-5.68M-16.1M-28.1M-27.0M-27.8M-28.8M-29.0M-50.4M-26.5M
Cash from investing3.01M-103.0K407.0K7.20M-126.0K157.0K8.99M607.0K22.7M-30.2M
Cash from financing1.39M2.98M9.36M3.24M39.5M5.40M18.3M43.9M605.0K3.03M
Share buybacks-124.0K16.4M43.0M625.0K751.0K
Change in cash-2.49M-2.80M-5.44M-17.6M12.8M-22.1M-1.20M17.3M-25.1M-51.8M